Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPL-0301 in Post-MI Left Ventricular Dysfunction
NCT05327855Phase 2Withdrawn
- Sponsor
- Valo Health
- Start
- Sep 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of OPL-0301 in left ventricular dysfunction (3 arms), sponsored by Valo Health. Primary endpoint: Infarct size as determined by cardiac magnetic resonance (CMR) at 90 days. Planned start Sep 2022; status: withdrawn.
02
Drugs
OPL-0301
03
Conditions
left ventricular dysfunction
Beyond the preview
Go deeper on NCT05327855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327855.